- Home
- EDUC vs MYNZ Comparison
EDUC vs MYNZ Comparison
Compare EDUC & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDUC | MYNZ |
|---|---|---|
| Founded | 1965 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 8.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDUC | MYNZ |
|---|---|---|
| Price | $1.32 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 20.0K | ★ 201.8K |
| Earning Date | 01-09-2026 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,415,900.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.92 |
| 52 Week High | $1.93 | $8.20 |
Technical Indicators
Market Signals| Indicator | EDUC | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 50.00 | 50.59 |
| Support Level | $1.26 | $1.09 |
| Resistance Level | $1.35 | $1.35 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 75.00 | 52.11 |
Price Performance
Historical ComparisonAbout EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.